A national shortage of blood components, especially platelets, have resulted in the need for creative ways of meeting the platelet needs of patients. Low-yield platelets are apheresis-derived platelets that contain less than 3.0 x 1011 platelets, which is the minimum required for a “standard-dose” platelet according to Food and Drug Administration regulations. Low-yield platelets may range from 2.6 to 2.9 x 1011 platelets which is approximately 10-15% fewer than a standard apheresis unit. The goal of this education session is to discuss the overall impact of low-yield platelets on blood centers, donors and recipients.
All relevant financial relationships have been mitigated.
Summarize current Food and Drug Administration regulations on platelet products.
Discuss current evidence for the safety and efficacy of low yield platelets in transfused patients.
Discuss the impact of low yield platelets on overall platelet supply.
Describe criteria for receiving low-yield platelet products and for billing.
PhD, MD, MS, CABP,
Director of Cellular Therapy Laboratory,
Columbia University Irving Medical Center